Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma Patients Receiving JNJ-79635322 and Human Normal Immunoglobulin (IV)

Registered drug

Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma Patients Receiving JNJ-79635322 and Human Normal Immunoglobulin (IV)

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Tocilizumab

Contact Research Centre

Adenocarcinoma pancreas

Recruiting

First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

Investigational

First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:(2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL]-2,7-DIAZASPIRO[4.4]NONAN-7-YL]-N-[(6S,8S,14S)-21-[5-(4-CYCLOPROPYLPIPERAZIN-1-YL)-2-[(1S)-1-METHOXYETHYL]PYRIDIN-3-YL]-18,18-DIMETHYL-9,15-DIOXO-22-(2,2,2-TRIFLUOROETHYL)-5,16-DIOXA-2,10,22,28-TETRAZAPENTACYCLO[18.5.2.12,6.110,14.023,27]NONACOSA-1(26),20,23(27),24-TETRAEN-8-YL]ACETAMIDE

Contact Research Centre

Polycythaemia vera

Recruiting

A Phase 3 Study of Sapablursen Compared with Placebo in Adults with Polycythemia Vera

Investigational

A Phase 3 Study of Sapablursen Compared with Placebo in Adults with Polycythemia Vera

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Sapablursen

Contact Research Centre

Plasma cell myeloma

Recruiting

Phase 3 study comparing linvoseltamab and daratumumab in high‑risk smoldering multiple myeloma patients

Registered drugNo placebo

Phase 3 study comparing linvoseltamab and daratumumab in high‑risk smoldering multiple myeloma patients

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Daratumumab

Contact Research Centre

Hepatocellular carcinoma

Recruiting

A Phase II Study of Cadonilimab Plus Lenvatinib Versus Lenvatinib in Advanced Hepatocellular Carcinoma After Atezolizumab/Bevacizumab Progression

Registered drugNo placebo

A Phase II Study of Cadonilimab Plus Lenvatinib Versus Lenvatinib in Advanced Hepatocellular Carcinoma After Atezolizumab/Bevacizumab Progression

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Lenvatinib

Contact Research Centre

Neovascular age-related macular degeneration

Recruiting

Efficacy and safety of ABP 938 compared with aflibercept in participants with neovascular age‑related macular degeneration

InvestigationalNo placebo

Efficacy and safety of ABP 938 compared with aflibercept in participants with neovascular age‑related macular degeneration

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Aflibercept

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Study of Pivekimab Sunirine Combined with Venetoclax and Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Registered drugNo placebo

Study of Pivekimab Sunirine Combined with Venetoclax and Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Azacitidine

Contact Research Centre

Follicular lymphoma

Recruiting

Study of AZD0486 plus rituximab versus standard chemotherapy drug combination in previously untreated follicular lymphoma patients

Registered drugNo placebo

Study of AZD0486 plus rituximab versus standard chemotherapy drug combination in previously untreated follicular lymphoma patients

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide

Contact Research Centre

Oesophageal adenocarcinoma

Recruiting

Durvalumab plus drug combination as total neoadjuvant therapy for patients with resectable gastroesophageal adenocarcinoma

Registered drugNo placebo

Durvalumab plus drug combination as total neoadjuvant therapy for patients with resectable gastroesophageal adenocarcinoma

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Calcium Folinate

Contact Research Centre

Dementia Alzheimer's type

Recruiting

Phase 2 Randomized Study of Mivelsiran in Adults with Early-Stage Down Syndrome-Associated Alzheimer’s Disease

Investigational

Phase 2 Randomized Study of Mivelsiran in Adults with Early-Stage Down Syndrome-Associated Alzheimer’s Disease

Investigational

Spain

Participants:18–64 years
Substances:ALN-961583

Contact Research Centre

Find therapies in clinical trials near you – page 4

761 trials match your criteria

Neoplasm

Long‑term Safety of Adagrasib with Drug Combination in Adults with Solid Tumors

Gastrooesophageal cancer+6

Study of Rinatabart Sesutecan with glatiramer acetate in patients with advanced gastrointestinal cancers

Plasma cell myeloma refractory

Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma Patients Receiving JNJ-79635322 and Human Normal Immunoglobulin (IV)

Adenocarcinoma pancreas

First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

Polycythaemia vera

A Phase 3 Study of Sapablursen Compared with Placebo in Adults with Polycythemia Vera

Plasma cell myeloma

Phase 3 study comparing linvoseltamab and daratumumab in high‑risk smoldering multiple myeloma patients

Hepatocellular carcinoma

A Phase II Study of Cadonilimab Plus Lenvatinib Versus Lenvatinib in Advanced Hepatocellular Carcinoma After Atezolizumab/Bevacizumab Progression

Neovascular age-related macular degeneration

Efficacy and safety of ABP 938 compared with aflibercept in participants with neovascular age‑related macular degeneration

Acute myeloid leukaemia

Study of Pivekimab Sunirine Combined with Venetoclax and Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Follicular lymphoma

Study of AZD0486 plus rituximab versus standard chemotherapy drug combination in previously untreated follicular lymphoma patients

Oesophageal adenocarcinoma

Durvalumab plus drug combination as total neoadjuvant therapy for patients with resectable gastroesophageal adenocarcinoma

Dementia Alzheimer's type

Phase 2 Randomized Study of Mivelsiran in Adults with Early-Stage Down Syndrome-Associated Alzheimer’s Disease

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.